Patients taking any of these medications along with semaglutide experience multiple simultaneous hits to b12 absorption
But researchers want to know what happens week by week
The cardiovascular benefits demonstrated in long-term trials are particularly relevant for patients with type 2 diabetes or established heart disease
Efficacy : Clinical trials for Wegovy report weight loss of around 15% on average, whereas Amycretin has demonstrated up to 22% weight loss in trials
Pemvidutide, a GLP-1/glucagon dual receptor agonist, significantly reduces liver fat, fibro-inflammation, and bodyweight in patients with non-alcoholic fatty liver disease: a 24-week multicenter, randomized, double-blind, placebo-controlled trial
If you feel ignored, ask for a short visit just to go over your logs and medication plan